Pfizer
PFE
$26.67
-0.49%
Pfizer Inc. is a global pharmaceutical giant primarily engaged in the discovery, development, and commercialization of prescription drugs and vaccines, operating within the Drug Manufacturers - General industry. The company is a market leader with a diversified portfolio anchored by blockbuster products like the pneumococcal vaccine Prevnar 13 and cardiology drugs Eliquis and Vyndaqel. The current investor narrative is dominated by the company's post-pandemic strategic pivot and resilience, as it navigates a significant revenue decline from its COVID-19 products while advancing its oncology pipeline, as evidenced by recent positive Phase 3 trial results for a prostate cancer combo therapy, and contends with a high-stakes regulatory environment including potential drug import tariffs.…
PFE
Pfizer
$26.67
Related headlines
Investment Opinion: Should I buy PFE Today?
Rating & Thesis: Hold. Pfizer presents a conflicted profile where attractive long-term valuation and income characteristics are offset by near-term earnings volatility and a stock price that appears disconnected from analyst fundamentals. The consensus analyst view, implied by a forward P/E-derived target of $21.63, suggests caution despite recent upgrades like Argus Research's move to Buy.
Supporting Evidence: The primary valuation metric, a forward P/E of 9.83x, is compelling and below sector peers, implying a discount if earnings materialize. The company maintains robust gross margins of 69.97% and generates immense free cash flow ($9.08B TTM) to fund its 6.9% dividend. However, revenue growth is stagnant (-1.16% YoY in Q4), and the stock trades at a -21.5% implied downside to the analyst-derived average target, indicating it may be overvalued on a near-term basis.
Risks & Conditions: The two biggest risks are failure to achieve the $2.20 forward EPS estimate and adverse regulatory developments on drug tariffs. This Hold rating would upgrade to a Buy if the stock price corrected towards the $22-$23 range (aligning with analyst targets) while the forward earnings story remains intact, or if Q1 2026 results show a return to consistent profitability without large one-time charges. It would downgrade to a Sell if revenue declines accelerate beyond -5% YoY or if the forward P/E expands above 12x without corresponding earnings growth. Based on the current price versus analyst targets, the stock appears overvalued in the near term.
Sign up to view all
PFE 12-Month Price Forecast
The outlook is balanced with a slight skew to the downside in the near term. The base case (55% probability) is a period of consolidation and proving out the earnings story, with the stock likely drifting towards analyst targets. The compelling forward valuation and high yield provide a floor, but the stock needs to demonstrate several quarters of clean, profitable execution to justify a higher multiple. The stance would upgrade to bullish on a pullback to the low $20s where the risk/reward improves markedly, or on clear evidence of sustained EPS growth. It would turn bearish if the next earnings report shows a repeat of Q4's significant loss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $34.67 and implied upside of +30.0% versus the current price.
Average Target
$34.67
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$21 - $35
Analyst target range
Pfizer is covered by 11 analysts, indicating substantial institutional interest. The consensus sentiment leans bullish, with recent actions including an upgrade from Argus Research from Hold to Buy in March 2026. The average target price is derived from an estimated EPS of $2.20, which, when applied to the forward PE of 9.83x, implies a target price of approximately $21.63, representing a -21.5% downside from the current price of $27.56. This negative implied upside suggests analyst models may be using a lower multiple or that the current price has run ahead of fundamental targets. The target range, inferred from estimated EPS, spans from a low of $2.12 to a high of $2.29. The high-end target assumes successful pipeline execution, margin stability, and no major competitive or regulatory setbacks. The low-end target likely factors in risks such as pricing pressure, clinical trial failures, or broader market multiple compression. The recent pattern of institutional ratings shows a mix of Buy and Neutral stances, with no outright Sell recommendations, but the wide implied spread between the current price and consensus targets indicates high uncertainty and a potential disconnect between market price action and analyst fundamental valuations.
Bulls vs Bears: PFE Investment Factors
The investment debate for Pfizer centers on a clash between near-term fundamental headwinds and long-term valuation appeal. The bear case currently holds stronger evidence, anchored by a significant disconnect between the stock price and analyst targets implying over 20% downside, coupled with recent earnings volatility. However, the bull case is supported by a compelling forward valuation discount, strong cash generation, and pipeline progress. The single most important tension is whether the company's pipeline execution and cost management can deliver the estimated $2.20 in forward EPS to justify the current price, or if ongoing revenue normalization and expense volatility will keep earnings depressed, validating the bearish analyst targets.
Bullish
- Strong Momentum Near 52-Week High: The stock is up 24.48% over the past year and is trading at $27.56, just 4.1% below its 52-week high of $28.75. This sustained recovery trend, with a 7.45% gain over the last three months, signals robust investor confidence in the company's post-pandemic pivot.
- Attractive Forward Valuation: Pfizer's forward P/E of 9.83x, based on estimated EPS of $2.20, is significantly below its trailing P/E of 18.21x and typical large-cap pharma multiples in the low-to-mid 20s. This suggests the market is pricing in a substantial earnings recovery, offering a potential valuation discount.
- The company generates strong free cash flow of $9.08 billion (TTM), underpinning its 6.9% dividend yield. A healthy balance sheet with a debt-to-equity ratio of 0.78 and a current ratio of 1.16 provides ample flexibility for R&D and strategic initiatives.
- Positive Pipeline Catalysts: Recent positive Phase 3 trial results for a prostate cancer combo therapy (Talzenna/Xtandi) demonstrate progress in the critical oncology pipeline. This provides a clear path to offsetting post-COVID revenue declines and diversifying the product portfolio.
Bearish
- Significant Earnings Volatility & Recent Loss: Q4 2025 results showed a net loss of -$1.65 billion (EPS -$0.29) due to $5.33 billion in other expenses, contrasting sharply with the prior quarter's profit. This inconsistency in bottom-line results creates uncertainty and complicates valuation.
- Analyst Targets Imply Major Downside: The analyst consensus, using a forward P/E of 9.83x and estimated EPS of $2.20, implies a target price of ~$21.63. This represents a -21.5% downside from the current price of $27.56, indicating the stock may have run ahead of fundamental valuations.
- Post-COVID Revenue Normalization: Q4 2025 revenue of $17.56B declined 1.16% YoY, following a volatile pattern from a peak of $17.76B in Q4 2024. The company is still stabilizing its base business after the wind-down of COVID-related sales, creating a near-term growth headwind.
- Regulatory & Competitive Tariff Risk: Recent news highlights the threat of 100% tariffs on imported drugs for companies without pricing deals. While Pfizer's status is unclear, this creates a stark regulatory divide and potential competitive moat disruption, adding a layer of political risk.
PFE Technical Analysis
Pfizer is in a sustained recovery trend, having gained 24.48% over the past year. With a current price of $27.56, the stock is trading at approximately 96% of its 52-week high of $28.75, indicating strong momentum but also proximity to a key technical resistance level that could signal overextension if breached. The stock is positioned near the top of its 52-week range ($21.87 to $28.75), suggesting investor optimism but also raising the risk of a pullback from these elevated levels. Recent momentum shows acceleration, with the stock up 7.45% over the last three months, outpacing the broader market's 2.67% gain as indicated by the SPY. However, the 1-month performance is more muted at +0.88%, which lags the SPY's 7.36% surge, resulting in a negative 1-month relative strength of -6.48. This divergence suggests short-term consolidation or underperformance relative to the market, potentially as the stock digests its longer-term gains and approaches resistance. Key technical support is anchored at the 52-week low of $21.87, while immediate resistance sits at the 52-week high of $28.75. A decisive breakout above $28.75 could signal a continuation of the bullish trend, whereas a failure could lead to a retracement towards support. The stock exhibits low market-relative volatility with a beta of 0.388, meaning it is roughly 61% less volatile than the SPY, which is a critical consideration for risk-averse investors seeking defensive exposure within healthcare.
Beta
0.39
0.39x market volatility
Max Drawdown
-17.9%
Largest decline past year
52-Week Range
$22-$29
Price range past year
Annual Return
+19.1%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | -1.1% | +8.5% |
| 3m | +4.0% | +2.8% |
| 6m | +7.7% | +4.6% |
| 1y | +19.1% | +32.3% |
| ytd | +5.9% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Pfizer's revenue trajectory reflects the post-pandemic normalization, with Q4 2025 revenue of $17.56 billion representing a year-over-year decline of 1.16%. This follows a volatile multi-quarter pattern where revenue peaked at $17.76 billion in Q4 2024, dipped to $13.22 billion in Q2 2024, and has since recovered, indicating the company is stabilizing its base business after the wind-down of COVID-related sales. The core Biopharma segment, valued at $30.58 billion annually, remains the primary growth driver outside of pandemic products. Profitability has been inconsistent, with the most recent quarter showing a net loss of -$1.65 billion, translating to negative EPS of -$0.29, largely due to significant other expenses of $5.33 billion. This contrasts sharply with the prior quarter's net income of $3.54 billion and EPS of $0.62. Gross margin remains robust at 69.97% for Q4 2025, consistent with the trailing twelve-month gross margin of 70.33%, indicating core pricing power and manufacturing efficiency despite bottom-line volatility. The balance sheet is healthy with a manageable debt-to-equity ratio of 0.78 and a current ratio of 1.16, reflecting adequate short-term liquidity. Crucially, the company generates substantial cash flow, with trailing twelve-month free cash flow of $9.08 billion, providing ample internal funding for dividends, R&D, and business development. Return on equity is modest at 8.99%, reflecting the recent profitability challenges, but the strong cash generation underpins financial flexibility.
Quarterly Revenue
$17.6B
2025-12
Revenue YoY Growth
-0.01%
YoY Comparison
Gross Margin
+0.69%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Given the company's positive trailing twelve-month net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. Pfizer's trailing PE stands at 18.21x, while its forward PE is significantly lower at 9.83x, based on estimated EPS of $2.20. This substantial gap implies the market expects a strong recovery in earnings over the next twelve months, nearly doubling from the depressed trailing figure. Compared to sector averages, Pfizer's valuation presents a mixed picture. Its trailing PE of 18.21x is below the typical range for large-cap pharma, which often trades in the low-to-mid 20s, suggesting a relative discount. This discount is further evidenced by its Price-to-Sales ratio of 2.26x and EV-to-Sales of 3.34x, which are conservative for the industry. The discount appears justified given the near-term earnings volatility and post-COVID revenue headwinds, but may not fully account for the stability of its core portfolio and pipeline catalysts. Historically, Pfizer's current trailing PE of 18.21x sits well below its own historical peaks seen during the pandemic (e.g., 1665x in Q2 2024 during an earnings trough) and is more aligned with its longer-term pre-pandemic averages. This positioning suggests the stock is not pricing in overly optimistic expectations and may offer value if the company successfully executes on its pipeline and cost management initiatives to meet forward earnings estimates.
PE
18.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~1666x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Pfizer faces significant earnings volatility, as evidenced by a swing from a $3.54B net income in Q3 2025 to a -$1.65B loss in Q4 2025, driven by large, irregular 'other expenses' of $5.33B. This inconsistency makes forecasting difficult. While revenue has stabilized around $17.5B quarterly post-COVID, the 1.16% YoY decline in Q4 2025 indicates the core business is not yet in a clear growth phase, creating dependence on pipeline successes to drive the top line. The high payout ratio of 125.8% (based on trailing EPS) suggests the dividend is not fully covered by recent earnings, though it is supported by strong cash flow.
Market & Competitive Risks: The stock trades at a premium to analyst fundamental targets, creating valuation compression risk if it fails to meet the high embedded expectations of a forward P/E of 9.83x. Externally, the emerging regulatory threat of 100% drug import tariffs creates a binary risk; if Pfizer is not among the exempted companies, it could face severe competitive and cost disadvantages. Furthermore, the stock's low beta of 0.388, while defensive, also means it may lag during strong bull markets, as seen in its recent 1-month underperformance versus the SPY.
Worst-Case Scenario: The most damaging scenario involves a combination of pipeline setbacks (e.g., further clinical trial stumbles like the Lyme vaccine), persistent high operational expenses eroding margins, and Pfizer being negatively impacted by new drug tariffs. This could trigger multiple compression towards the bear-case analyst target and a retest of the 52-week low. From the current price of $27.56, a decline to the 52-week low of $21.87 represents a realistic downside of approximately -21%. Adding in the potential for missed earnings estimates, the total downside in an adverse scenario could reasonably reach -25% to -30%.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: The company just reported a Q4 net loss of -$1.65B, and similar large, irregular charges could recur, jeopardizing the forward EPS target. 2) Valuation & Sentiment Risk: The stock trades at a premium to analyst targets, creating high downside risk if sentiment sours. 3) Regulatory Risk: Potential 100% tariffs on imported drugs could disrupt competitive dynamics if Pfizer is not exempted. 4) Execution Risk: The company's strategic pivot relies on pipeline successes like the prostate cancer therapy; clinical or commercial failures would delay growth.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $21.63 and $25.00 as it works towards its forward EPS target, aligning with analyst averages. The Bull Case (25% probability) targets $28.75 to $32.00 on successful pipeline execution and multiple expansion. The Bear Case (20% probability) warns of a drop to the $20.00-$21.87 range if earnings disappoint and sentiment deteriorates. The most likely outcome is the Base Case, predicated on the assumption that Pfizer meets, but does not significantly exceed, its $2.20 EPS estimate for 2026.
The answer depends on the timeframe. On a forward-looking basis, PFE appears undervalued with a forward P/E of 9.83x, which is a discount to large-cap pharma peers and its own historical averages. This implies the market expects a strong earnings recovery to an estimated $2.20 EPS. However, based on current analyst price targets derived from that multiple, the stock is overvalued by approximately 21.5%. The market is currently pricing in a more optimistic multiple or faster earnings growth than analysts project. Therefore, it is fairly valued only if the bullish earnings scenario materializes promptly.
PFE is a conflicted buy at its current price of $27.56. For income-seeking, long-term investors with a high risk tolerance for earnings volatility, the 6.9% dividend yield and low valuation (forward P/E of 9.83x) are attractive. However, the stock appears overvalued in the near term, with analyst models implying a -21.5% downside to ~$21.63. It could be a good buy on a significant pullback that closes this gap, or for investors who strongly believe the company will exceed its forward earnings estimates. For most, it is better suited as a 'Hold' until the earnings trajectory becomes clearer.
PFE is primarily suitable for long-term investment (3-5 year horizon). Its low beta (0.388) and high dividend yield are hallmarks of a long-term, income-generating holding. The company's value proposition hinges on pipeline development and earnings stabilization, which are multi-year processes. It is poorly suited for short-term trading due to its low volatility and recent pattern of lagging the market during rallies. Investors should be prepared to hold through quarterly earnings volatility to capture the dividend and await potential multiple expansion. A minimum holding period of 18-24 months is suggested to assess the success of the strategic pivot.